VEGFA and aneurysmal bone cyst: This study is the first demonstration of the clinical value of a vascular response biomarker in the setting of VEGF RTKi-treated patients, and importantly, it shows that there is a group of patients with ABC who gain clinically significant improvements in PFS and OS from cediranib.